RECARDIO is a Phase 2 life science company focusing on drug and cell based regenerative therapies for cardiovascular diseases. The company is located in San Francisco, California, and is having its operations in USA, Europe and Asia.

The company’s lead drug candidate, dutogliptin, is a DPP-IV inhibitor that has demonstrated significant effects in activating SDF-1, a protein that is critical for stem cell based cardiac regeneration. After FDA approval in January 2018 the company has initiated a global Phase 2 clinical program, seeking to fully develop the therapeutic platform as a regenerative medication for patients with various cardiovascular diseases including acute myocardial infarction and chronic heart failure, with the potential of improving heart function, quality of life and survival.
Organizational Logo

Contact Recardio
Visit Website